Bridgeway Capital Management’s Perspective Therapeutics CATX Stock Holding History

Bridgeway Capital Management’s Portfolio CATX Stock Details CATX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$462K	Buy	110,800 +15,000	+16%	+$63.4K	0.01%	836
2025 Q4	$263K	Hold	95,800	–	–	0.01%	966
2025 Q3	$329K	Sell	95,800 -15,000	-14%	-$54.7K	0.01%	898
2025 Q2	$381K	Sell	110,800 -14,200	-11%	-$37.5K	0.01%	818
2025 Q1	$266K	Buy	+125,000	New	+$375K	0.01%	860
2024 Q3	–	Sell	-13,400	Closed	-$134K	–	1267
2024 Q2	$134K	Sell	13,400 -5,000	-27%	-$72.3K	﹤0.01%	1132
2024 Q1	$219K	Hold	18,400	–	–	﹤0.01%	1095
2023 Q4	$74K	Hold	18,400	–	–	﹤0.01%	1282
2023 Q3	$50.4K	Hold	18,400	–	–	﹤0.01%	1303
2023 Q2	$123K	Hold	18,400	–	–	﹤0.01%	1226
2023 Q1	$117K	Hold	18,400	–	–	﹤0.01%	1205
2022 Q4	$45.5K	Hold	18,400	–	–	﹤0.01%	1306
2022 Q3	$42K	Hold	18,400	–	–	﹤0.01%	1360
2022 Q2	$57K	Hold	18,400	–	–	﹤0.01%	1274
2022 Q1	$67K	Hold	18,400	–	–	﹤0.01%	1282
2021 Q4	$71K	Sell	18,400 -9,000	-33%	-$48K	﹤0.01%	1234
2021 Q3	$173K	Hold	27,400	–	–	﹤0.01%	1214
2021 Q2	$219K	Sell	27,400 -26,000	-49%	-$228K	﹤0.01%	1249
2021 Q1	$582K	Buy	53,400 +35,000	+190%	+$529K	0.01%	1052
2020 Q4	$83K	Sell	18,400 -10,000	-35%	-$44.2K	﹤0.01%	1278
2020 Q3	$166K	Hold	28,400	–	–	﹤0.01%	1196
2020 Q2	$158K	Buy	+28,400	New	+$183K	﹤0.01%	1181
2019 Q2	–	Sell	-16,870	Closed	-$62K	–	1323
2019 Q1	$62K	Hold	16,870	–	–	﹤0.01%	1304
2018 Q4	$51K	Sell	16,870 -980	-5%	-$4.2K	﹤0.01%	1336
2018 Q3	$93K	Hold	17,850	–	–	﹤0.01%	1386
2018 Q2	$80K	Hold	17,850	–	–	﹤0.01%	1377
2018 Q1	$75K	Sell	17,850 -5,000	-22%	-$22.1K	﹤0.01%	1343
2017 Q4	$91K	Hold	22,850	–	–	﹤0.01%	1344
2017 Q3	$118K	Hold	22,850	–	–	﹤0.01%	1328
2017 Q2	$143K	Hold	22,850	–	–	﹤0.01%	1328
2017 Q1	$135K	Hold	22,850	–	–	﹤0.01%	1317
2016 Q4	$133K	Sell	22,850 -4,660	-17%	-$28.5K	﹤0.01%	1348
2016 Q3	$198K	Hold	27,510	–	–	﹤0.01%	1323
2016 Q2	$239K	Hold	27,510	–	–	﹤0.01%	1269
2016 Q1	$248K	Hold	27,510	–	–	﹤0.01%	1261
2015 Q4	$258K	Buy	27,510 +6,030	+28%	+$75.1K	﹤0.01%	1246
2015 Q3	$301K	Buy	21,480 +5,000	+30%	+$72.2K	0.01%	1216
2015 Q2	$244K	Buy	16,480 +500	+3%	+$8.1K	﹤0.01%	1310
2015 Q1	$251K	Buy	15,980 +980	+7%	+$14.5K	0.01%	1291
2014 Q4	$219K	Buy	+15,000	New	+$238K	0.01%	1285

Other funds holding CATX

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bridgeway Capital Management's CATX Position: Q1 2026 in Review

Bridgeway Capital Management increased its Perspective Therapeutics (CATX) stake by 16% in Q1 2026, buying an estimated $63.4K and bringing the position to 110,800 shares worth $462K. The position accounts for 0.01% of the portfolio, ranked #836.

Bridgeway Capital Management first reported a position in CATX in Q4 2014 and has held it in 40 quarters since. The position peaked at $582K in Q1 2021. 138 funds tracked by Wall St. Rank hold CATX as of Q1 2026.

Bridgeway Capital Management held 110,800 shares of Perspective Therapeutics worth $462K as of Q1 2026.
Bridgeway Capital Management bought 15,000 Perspective Therapeutics shares in Q1 2026, an estimated $63.4K.
Perspective Therapeutics made up 0.01% of Bridgeway Capital Management's portfolio in Q1 2026, its #836 holding.
Bridgeway Capital Management first reported a position in Perspective Therapeutics in Q4 2014 and has held it in 40 quarters since.
Bridgeway Capital Management's Perspective Therapeutics position peaked at $582K in Q1 2021.
138 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.